Modulation of tumour-induced bone resorption by bisphosphonates.
Tumour cells produce systemic or local factors which can stimulate osteoclast development and activity leading to increased bone resorption. The clinical consequences are bone pain, fractures and hypercalcaemia. Inhibitors of osteoclast-mediated bone resorption, such as the bisphosphonates, are now the treatment of choice for tumour-induced hypercalcaemia. Recent evidence indicates that these compounds, especially the newer ones, reduce skeletal morbidity in patients with metastatic bone disease and improve their quality of life. Better understanding of the mechanisms underlying tumour-induced bone resorption and development of more potent and less toxic bisphosphonates will lead to improved management of patients with malignant diseases involving the skeleton.
Papapoulos
S E
SE
Department of Endocrinology, University Hospital, Leiden, The Netherlands.
van Holten-Verzantvoort
A T
AT
D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*
D004164:Diphosphonates